Investigating the Clinical Benefit of Selumetinib in Resensitising Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy: Results of the SEL-I-METRY Phase II Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Investigating the Clinical Benefit of Selumetinib in Resensitising Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy: Results of the SEL-I-METRY Phase II Trial

Published:2022 Issue: Volume: Page:
ISSN:1556-5068
Container-title:SSRN Electronic Journal
language:en
Short-container-title:SSRN Journal

Author:

Wadsley Jonathan,Ainsworth Gemma,Coulson Amy Beth,Garcez Kate,Moss Laura,Newbold Kate,Farnell Kate,Swain Jayne,Howard Helen,Beasly Matthew,Weaver Andrew,Wood Katie,Marshall Jennifer,Griffin Matthew,Pascoe Abigail,Du Yong,Taprogge Jan,Flux Glenn,Brown Sarah

Publisher

Elsevier BV

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference15 articles.

1. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial;M S Brose;Lancet,2014

2. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy;C Durante;J Clin Endocr Metab,2006

3. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies;Y Y Liu;Clin Endocrinol,2006

4. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma;S M Coelho;J Endocrinol Invest,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP